FDA Peptide Reclassification 2026: What It Means for Providers The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying